ANAPHYLAXIS AND VACCINATION: RISKS AND REALITIES
https://doi.org/10.21508/1027-4065-2018-63-4-15-22
Abstract
The article is about the problem of anaphylaxis in the post-vaccination period. Data on the frequency of its prevalence and lethality depending on the type of vaccine are presented. Variants of a clinical picture of anaphylaxis and differential-diagnostic approaches are indicated. The major causal components of vaccines, anaphylaxis inducers, and methods for their identification are mentioned. Therapeutic approaches are analyzed, false myths and contraindications to vaccination are indicated. The experience of carrying out preventive individual measures is generalized.
About the Authors
A. P. Ruban
Belarusian Medical Academy of Postgraduate Education
Belarus
Belarus
A. N. Pampura
Research and Clinical Institute for Pediatrics named after Academician Yu.E. Veltischev of the Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
References
1. Demoly P. Adkinson N.F., Brockow K., Castells M., Chiriac A.M., Greenberger P.A. et al. International Consensus (ICON) on drug allergy. Allergy 2014; 69(4): 420–437. DOI:10.1111/all.12350
2. Vaccine safety basics. Available at: http://ru.vaccine-safety-training.org/home. html. Accessed 2013. (in Russ)
3. Epidemiology and Prevention of Vaccine-preventable diseases. Pink Book, 2015; https://www.cdc.gov/vaccines/pubs/pinkbook/index.html.
4. Simons F.E., Ardusso L.R., Bilo M.B., Cardona V., Ebisawa M., El-Gamal Y.M. et al. International consensus on (ICON) anaphylaxis. World Allergy Organ J 2014; 7(9): 1–19. DOI: 10.1186/1939-4551-7-9
5. Muraro A., Roberts G., Worm M., Bilo M.B., Brockow K., Fernández Rivas M. et al. Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. Allergy 2014; 69(8): 1026–1045. doi: 10.1111/all.12437
6. Sargant N., Erlewyn-Lajeunesse M., Benger J. Does anaphylaxis masquerade as asthma in children? Emerg Med J 2015; 32: 83–84. DOI:10.1136/emermed-2014-203603
7. Echeverri a-Zudaire L.A., Ortigosa-del Castillo L., Alonso-Lebrero E., Alvares-Garcia F.J., Cortes-Alvares N. et al. Consensus document on the approach to children with allergic reactions after vaccination or allergy to vaccine components. Allergol Immunopathol (Madr) 2015; 43: 304–325. DOI:10.1016/j.aller.2015.01.004
8. McNeil M.M., Weintraub E.S., Duffy J., Sucumaran L., Jacobsen S.G., Klein N.P. et al. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol 2016; 137(3): 868–878. DOI: 10.1016/j.jaci.2015.07.048
9. Plotkin S.A. Vaccines. Elsevier Science: W.B. Saunders Company, 6th Edition, 2012; 1576.
10. Report of the Committee on Infectious Diseases. American Academy of Pediatrics. Red Book 2015; http://ebooks.aappublications.org/content/red-book-30th-edition-2015.
11. Erlewyn-Lajeunesse M., Hunt L.P., Heath P.T., Finn A. Anaphylaxis as an adverse event following immunisation in the UK and Ireland. Arch Dis Child 2012; 97(6): 487–490. DOI:10.1111/j.1365-2214.2012.01418_3.x
12. Ruggeberg J.U., Gold M.S., Bayas J.M., Blum M.D., Bonhoeffer J., Friedlander S. et al. Anaphylaxis: case definition and guidelines for data collection, analysis and presentation of immunization safety data. Vaccine 2007; 25: 5675–5684.
13. Hox V., Desai A., Bandara G., Gilfillan A.M., Metcalfe D.D., Olivera A. Estrogen increases the severity of anaphylaxis in female mice through enhanced endothelial nitric acid oxide synthetase expression and nitric oxide production. J Allergy Clin Immunol 2015; 135: 729–736.
14. Helbling A., Hurni T., Mueller U.R., Pichler W.J. Incidence of anaphylaxis with circulatory symptoms: A study over a 3-year period comprising 940000 inhabitants of the swiss canton bern. Clin Exp Allergy 2004; 34: 285–290.
15. Calvani M., Cardinale F., Martelli A., Muraro A., Pucci N., Savino F. et al. Italian Society of Pediatric Allergy and Immunology (SIAIP) Anaphylaxis’ Study Group. Risk factors for severe pediatric food anaphylaxis in Italy. Pediatr Allergy Immunol 2011; 22(8): 813–819.
16. Shmeleva N.D. Characteristics of post-vaccination complications after introduction of a national vaccination calendar in the Republic of Belarus. Medicinskaja panorama 2012; 2: 48–51. (in Russ)
17. Gee J., Weinbaum C., Sukumaran L., Markowitz L.E. Human Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States. Vaccines & Immunotherapeutics 2016; 12(6): 1406–1417. DOI:10.1080/21645515.2016.1168952
18. Brotherton J.M., Gold M.S., Kemp A.S., McIntyre P.B., Burgess M.A., Campbell-Lloyd S. New South Wales Health HPV Adverse Events Panel. Anaphylaxis following quadrivalent human papillomavirus vaccination. CMAJ 2008; 179(6): 525–533.
19. Nakayama T., Onoda K. Vaccine adverse events reported in post-marketing study of the Kitasato Institute from 1994 to 2004. Vaccine 2007; 25: 570–576.
20. Zhou W., Pool V., Iskander J.K., English-Bullard R., Ball R., Wise R.P. et al. Surveillance for safety after immunization: vaccine adverse event reporting system (VAERS) – United States, 1991–2001. MMWR Surveill Summ 2003; 52(1): 1–24.
21. Vellozzi C., Burwen D.R., Dobardzic A., Ball R., Walton K., Haber P. Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring. Vaccine 2009; 27(15): 2114–2120.
22. Simons F.E., Clark S., Camargo C.A.Jr. Anaphylaxis in the community: learning from the survivors. J Allergy Clin Immunol 2009; 124(2): 301–306.
23. Pampura A.N., Konyukova N.G. Anaphylaxis on food products in young children. Ros vestn perinatol i pediatr 2011; 56(5): 76–84. (in Russ)
24. Popa V.T., Lerner S.A. Biphasic systemic anaphylactic reactions: three illustrative cases. Ann Allergy 1984; 53: 151–155.
25. Lieberman P. Biphasic anaphylactic reactions. Ann Allergy Asthma Immunol 2005; 95(3): 217–226.
26. Nagao M., Fujisawa T., Ihara T., Kino Y. Highly increased levels of IgE antibodies vaccine components in children with influenza vaccine-associated anaphylaxis. J Allergy Clin Immunol 2016; 137: 861–867. DOI:10.1016/j.jaci.2015.08.001
27. Arroabarren E., Anda M., Sanz M.L. Anaphylaxis to pneumococcal vaccine; CRM (197): novel cause of vaccine allergy. Pediatr Allergy Immunol 2016; 27: 425–437. DOI:10.1111/pai.12548
28. Adverse effects of vaccines: evidence and causality. Stratton K., Ford A., Rusch E., Clayton E.W., (eds). Washington (DC): Institute of Medicine: National Academies Press, 2011; 70–78.
29. Erlewyn-Lajeunesse M., Brathwaite N., Lucas J., Warner J. Recommendations for the administration of influenza vaccine in children allergic to egg. BMJ 2009; 339: b3680.
30. Dreskin S.C., Halsey N.A., Kelso J.M., Wood R.A., Edwards D.S., Edwards K.M. et al. International Consensus (ICON): allergic reactions to vaccines. World Allergy Organ J 2016; 9(1): 32. doi:10.1186/s40413-016-0120-5
31. On the approval of instructions on the tactics of carrying out preventive vaccinations among the population in the Republic of Belarus. Order Min. Healthy. of the Republic of Belarus No. 191 of February 27, 2014. Available at: http://naviny. org/2014/02/27/by3741.htm. Accessed 2014. (in Russ)
32. Vaccines and vaccinations. National guidelines. V.V. Zverev, B.F. Semenov, R.M. Khaitov (eds). Moscow: GEOTAR-Media, 2011; 872. (in Russ)
33. Kelso J.M., Jones R.T., Yunginger J.W. Anaphylaxis to measles, mumps, and rubella vaccine mediated by IgE to gelatin. J Allergy Clin Immunol 1993; 91: 867–872.
34. DiMiceli L., Pool V., Kelso J.M., Shadomy S.V., Iskander J., VAERS Team. Vaccination of yeast sensitive individuals: review of safety data in the US Vaccine Adverse Event Reporting System (VAERS). Vaccine 2006; 24: 703–707.
35. Russell M., Pool V., Kelso J.M., Tomazic-Jezic V.J. Vaccination of persons allergic to latex: a review of safety data in the Vaccine Adverse Event Reporting System (VAERS). Vaccine 2004; 23: 664–667.
36. Kattan J.D., Konstantinou G.N., Cox A.L., Nowak-Wegrzyn A., Gimenez G., Sampson H.A. et al. Anaphylaxis to diphtheria, tetanus, and pertussis vaccines among children with cow’s milk allergy. J Allergy Clin Immunol 2011; 128: 215–218.
37. Nakayama T., Aizawa C., Kuno-Sakai H. A clinical analysis of gelatin allergy and determination of its causal relationship to the previous administration of gelatin-containing acellular pertussis vaccine combined with diphtheria and tetanus toxoids. J Allergy Clin Immunol 1999; 103(2 Pt 1): 321–325.
38. Pool V., Braun M.M., Kelso J.M., Mootrey G., Chen R.T., Yunginger J.W. et al.; VAERS Team. US Vaccine Adverse Event Reporting System. Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States. Pediatrics 2002; 110(6): e71.
39. Lavi S., Zimmerman B., Koren G., Gold R. Administration of measles, mumps and rubella virus vaccine (live) to eggallergic children. JAMA 1990; 263: 269–271.
40. De Silva R., Dasanayake W., Wickramasinhe G.D., Karunatilake C., Weerasinghe N., Gunasekera P. et al. Sensitization to bovine serum albumin as a possible cause of allergic reactions to vaccines. Vaccine 2017; 35(11): 1494–1500. DOI:10.1016/j.vaccine.2017.02.009
41. Kattan J., Konstantinou G., Cox A., Nowak-Wegrzyn A., Gimenez G., Sampson H.A. et al. Anaphylaxis to diphtheria, tetanus, and pertussis vaccines among children with cow’s milk allergy. J Allergy Clin Immunol 2011; 128: 215–218. DOI:10.1016/j.jaci.2011.04.046
42. Clinical protocols for diagnosis and treatment of allergic diseases in children. Order Min. Healthy. Republic of Belarus from 08.08.2014 No 829; http://minzdrav.gov.by/upload/dadvfiles/000913_270327_829.pdf-. Accessed 08.12.2014. (in Russ)
43. Russian Association of Allergologists and Clinical Immunologists. Federal clinical guidelines for the diagnosis and therapy of anaphylaxis. Moscow 2015; http://nrcii.ru/docs/KR_po_anafilaksii_24.12.2015.pdf. (in Russ)
44. Instructions for the medical use of the drug. http://rceth.by/NDfiles/instr/9045_94_99_04_07_09_14_s.pdf. Accessed 08.12.2017. (in Russ)
45. Choo K., Simons F.E., Sheikh A. Glucocorticoids for the treatment of anaphylaxis: Cochrane Database Syst Rev 2012; CD007596.
46. Allergology and Immunology. National guideline. R.M. Khaitov, N.I. Il’ina (eds). Moscow: GEOTAR-Media 2009; 656. (in Russ)
47. Shamsheva O.V., Uchaykin V.F., Medunitsyn N.V. Clinical Vaccinology. Moscow: GEOTAR-Media 2016; 576. (in Russ)
48. De Silva H., Pathmeswaran A., Ranasinha C., Jayamanne S., Samarakoon B., Hittharage A. et al. Low-Dose Adrenaline, Promethazine, and Hydrocortisone in the Prevention of Acute Adverse Reactions to Antivenom following Snakebite: A Randomized, Double-Blind, Placebo-controlled Trial. PLOS Med 2011; 8: e1000435.
49. Tramer M., von Elm E., Loubeyre P., Hauser C. Pharmacological prevention of serious anaphylactic reactions due to iodinated contrast media: systematic review. BMJ 2006; 333: 675.
Review
For citations:
Ruban A.P., Pampura A.N. ANAPHYLAXIS AND VACCINATION: RISKS AND REALITIES. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2018;63(4):15-22. (In Russ.) https://doi.org/10.21508/1027-4065-2018-63-4-15-22
Views:
2243
Email this article 